124 related articles for article (PubMed ID: 19075531)
1. [Pharmacological profiles and clinical effects of blonanserin (Lonasen) on schizophrenia].
Ishibashi T; Nishikawa H; Une T; Nakamura H
Nihon Yakurigaku Zasshi; 2008 Dec; 132(6):351-60. PubMed ID: 19075531
[No Abstract] [Full Text] [Related]
2. Blonanserin: a review of its use in the management of schizophrenia.
Deeks ED; Keating GM
CNS Drugs; 2010 Jan; 24(1):65-84. PubMed ID: 20030420
[TBL] [Abstract][Full Text] [Related]
3. [Blonanserin in the treatment of schizophrenia].
Tenjin T; Miyamoto S
Nihon Rinsho; 2013 Apr; 71(4):660-5. PubMed ID: 23678596
[TBL] [Abstract][Full Text] [Related]
4. The atypical antipsychotic blonanserin reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets.
Kotani M; Enomoto T; Murai T; Nakako T; Iwamura Y; Kiyoshi A; Matsumoto K; Matsumoto A; Ikejiri M; Nakayama T; Ogi Y; Ikeda K
Behav Brain Res; 2016 May; 305():212-7. PubMed ID: 26970575
[TBL] [Abstract][Full Text] [Related]
5. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range.
Baba S; Enomoto T; Horisawa T; Hashimoto T; Ono M
J Pharmacol Sci; 2015 Mar; 127(3):326-31. PubMed ID: 25837930
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial.
Yang J; Bahk WM; Cho HS; Jeon YW; Jon DI; Jung HY; Kim CH; Kim HC; Kim YK; Kim YH; Kwon JS; Lee SY; Lee SH; Yi JS; Yoon BH; Kim SH
Clin Neuropharmacol; 2010 Jul; 33(4):169-75. PubMed ID: 20661022
[TBL] [Abstract][Full Text] [Related]
7. Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients.
Yasui-Furukori N; Kaneda A; Sugawara N; Tomita T; Kaneko S
J Psychopharmacol; 2012 Jun; 26(6):806-12. PubMed ID: 21616975
[TBL] [Abstract][Full Text] [Related]
8. The position of blonanserin as a treatment for schizophrenia.
Kishi T; Matsuda Y; Iwata N
Asia Pac Psychiatry; 2014 Dec; 6(4):462. PubMed ID: 25425069
[No Abstract] [Full Text] [Related]
9. Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances.
Inoue Y; Tsuchimori K; Nakamura H
J Pharmacol Sci; 2021 Jan; 145(1):42-51. PubMed ID: 33357778
[TBL] [Abstract][Full Text] [Related]
10. Use of Blonanserin Transdermal Patch in Home Treatment of Schizophrenia: A Case Study.
Ogawa T; Tachikawa H; Shiratori Y; Sodeyama N; Taguchi T; Hori T; Arai T
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):603-605. PubMed ID: 34433201
[No Abstract] [Full Text] [Related]
11. Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia.
Tenjin T; Miyamoto S; Miyake N; Ogino S; Kitajima R; Ojima K; Arai J; Teramoto H; Tsukahara S; Ito Y; Tadokoro M; Anai K; Funamoto Y; Kaneda Y; Sumiyoshi T; Yamaguchi N
Hum Psychopharmacol; 2012 Jan; 27(1):90-100. PubMed ID: 22278973
[TBL] [Abstract][Full Text] [Related]
12. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials.
Kishi T; Matsuda Y; Nakamura H; Iwata N
J Psychiatr Res; 2013 Feb; 47(2):149-54. PubMed ID: 23131856
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Kishi T; Matsui Y; Matsuda Y; Katsuki A; Hori H; Yanagimoto H; Sanada K; Morita K; Yoshimura R; Shoji Y; Hagi K; Iwata N
Pharmacopsychiatry; 2019 Feb; 52(2):52-62. PubMed ID: 29514360
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological study on second-generation antipsychotic agents and the effects on improvement of cognitive function in patients with schizophrenia].
Kuroki T
Seishin Shinkeigaku Zasshi; 2006; 108(12):1323-9. PubMed ID: 17396387
[No Abstract] [Full Text] [Related]
15. Long-term efficacy and safety of blonanserin in patients with first-episode schizophrenia: a 1-year open-label trial.
Ninomiya Y; Miyamoto S; Tenjin T; Ogino S; Miyake N; Kaneda Y; Sumiyoshi T; Yamaguchi N
Psychiatry Clin Neurosci; 2014 Dec; 68(12):841-849. PubMed ID: 24835911
[TBL] [Abstract][Full Text] [Related]
16. The relationship between the plasma concentration of blonanserin, and its plasma anti-serotonin 5-HT(2A) activity/anti-dopamine D₂ activity ratio and drug-induced extrapyramidal symptoms.
Suzuki H; Gen K
Psychiatry Clin Neurosci; 2012 Mar; 66(2):146-52. PubMed ID: 22353327
[TBL] [Abstract][Full Text] [Related]
17. [Research progress in mechanisms and clinical application for blonanserin and lurasidone in improving cognitive function of schizophrenia].
Zheng Q; Liu B; Xu S; Liao M; Zhang Y; Li L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 42(4):476-480. PubMed ID: 28490709
[TBL] [Abstract][Full Text] [Related]
18. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
Miura I; Shiga T; Katsumi A; Kanno-Nozaki K; Mashiko H; Niwa S; Yabe H
Hum Psychopharmacol; 2014 Mar; 29(2):199-202. PubMed ID: 24590545
[TBL] [Abstract][Full Text] [Related]
19. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder.
Ratti E; Bellew K; Bettica P; Bryson H; Zamuner S; Archer G; Squassante L; Bye A; Trist D; Krishnan KR; Fernandes S
J Clin Psychopharmacol; 2011 Dec; 31(6):727-33. PubMed ID: 22020354
[TBL] [Abstract][Full Text] [Related]
20. Three cases of schizophrenia showing improvement after switching to blonanserin.
Kurotaki N; Nobata H; Nonaka S; Nishihara K; Ozawa H
Psychiatry Clin Neurosci; 2011 Jun; 65(4):396-7. PubMed ID: 21682816
[No Abstract] [Full Text] [Related]
[Next] [New Search]
